Essais liés11clinical trials
VilleValencialocalisation
PaysSpainlocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT05639114

Ouvrir le site du centre

Essais cliniques associés

11
MoléculeIndication / populationPhaseNCTTitreStatut
rapcabtagene autoleucel Lupus Phase 2 NCT06581198 A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) ACTIVE_NOT_RECRUITING
Remibrutinib (Blinded) SEP Phase 3 NCT07225504 REMASTER — A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis RECRUITING
VHB937 Sclérose latérale amyotrophique Phase 2 NCT06643481 ASTRALS — A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) ACTIVE_NOT_RECRUITING
Ianalumab Lupus Phase 3 NCT05639114 Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) ACTIVE_NOT_RECRUITING
rapcabtagene autoleucel (YTB323) SEP Phase 1/2 NCT06617793 An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis ACTIVE_NOT_RECRUITING
Remibrutinib (Blinded) Myasthénie Phase 3 NCT06744920 RELIEVE — A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis RECRUITING
Iptacopan Myasthénie Phase 3 NCT06517758 A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. ACTIVE_NOT_RECRUITING
Remibrutinib oral treatment SEP Phase 3 NCT06846281 Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. RECRUITING
Interferon beta-1a SEP Phase 3 NCT01892722 Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis ACTIVE_NOT_RECRUITING
Ianalumab Lupus Phase 3 NCT06133972 Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). RECRUITING
RAD001 Épilepsie Phase 3 NCT01713946 A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures COMPLETED